Last reviewed · How we verify

Teneligliptin/Canagliflozin

Tanabe Pharma Corporation · Phase 3 active Small molecule

Teneligliptin/Canagliflozin is a DPP-4 inhibitor, SGLT2 inhibitor Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Type 2 diabetes mellitus, Hypertension. Also known as: Tenelia, MP-513, Canaglu, TA-7284.

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Used for Type 2 diabetes mellitus, Hypertension.

At a glance

Generic nameTeneligliptin/Canagliflozin
Also known asTenelia, MP-513, Canaglu, TA-7284
SponsorTanabe Pharma Corporation
Drug classDPP-4 inhibitor, SGLT2 inhibitor
TargetDPP-4, SGLT2
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Teneligliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones. This leads to increased insulin release and decreased glucagon levels in the circulation in a glucose-dependent manner. Canagliflozin, on the other hand, works by inhibiting the reabsorption of glucose in the kidneys, thereby increasing glucose excretion in the urine and lowering blood glucose levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Teneligliptin/Canagliflozin

What is Teneligliptin/Canagliflozin?

Teneligliptin/Canagliflozin is a DPP-4 inhibitor, SGLT2 inhibitor drug developed by Tanabe Pharma Corporation, indicated for Type 2 diabetes mellitus, Hypertension.

How does Teneligliptin/Canagliflozin work?

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

What is Teneligliptin/Canagliflozin used for?

Teneligliptin/Canagliflozin is indicated for Type 2 diabetes mellitus, Hypertension.

Who makes Teneligliptin/Canagliflozin?

Teneligliptin/Canagliflozin is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

Is Teneligliptin/Canagliflozin also known as anything else?

Teneligliptin/Canagliflozin is also known as Tenelia, MP-513, Canaglu, TA-7284.

What drug class is Teneligliptin/Canagliflozin in?

Teneligliptin/Canagliflozin belongs to the DPP-4 inhibitor, SGLT2 inhibitor class. See all DPP-4 inhibitor, SGLT2 inhibitor drugs at /class/dpp-4-inhibitor-sglt2-inhibitor.

What development phase is Teneligliptin/Canagliflozin in?

Teneligliptin/Canagliflozin is in Phase 3.

What are the side effects of Teneligliptin/Canagliflozin?

Common side effects of Teneligliptin/Canagliflozin include Nasopharyngitis, Hypoglycemia, Ketoacidosis, Urosepsis, Urinary Tract Infection.

What does Teneligliptin/Canagliflozin target?

Teneligliptin/Canagliflozin targets DPP-4, SGLT2 and is a DPP-4 inhibitor, SGLT2 inhibitor.

Related